Judy C Chang1, Cynthia L Holland2, Jill A Tarr2, Doris Rubio3, Keri L Rodriguez3,4, Kevin L Kraemer3, Nancy Day5, Robert M Arnold3,6. 1. 1 Department of Obstetrics, Gynecology and Reproductive Sciences and General Internal Medicine, Magee-Womens Research Institute, and the Center for Research in Health Care, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. 2 Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, Pittsburgh, Pennsylvania. 3. 3 Division of General Internal Medicine, Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. 5 Center for Health Equity Research & Promotion (CHERP), VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 5. 4 Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. 6 Institute to Enhance Palliative Care, and Director, Pittsburgh, Pennsylvania.
Abstract
PURPOSE: To assess use, screening, and disclosure of perinatal marijuana and other illicit drugs during first obstetric visits. DESIGN: Observational study that qualitatively assesses provider screening and patient disclosure of substance use. SETTING: Study sites were five urban outpatient prenatal clinics and practices located in Pittsburgh, Pennsylvania. PARTICIPANTS: Pregnant patients and obstetric providers were recruited as participants. METHODS: We audio recorded patient-provider conversations during first obstetric visits and obtained patient urine samples for drug analyses. Audio recordings were reviewed for provider screening and patient disclosure of illicit drug use. Urine analyses were compared with audio recordings to determine disclosure. RESULTS: Four hundred and twenty-two pregnant patients provided complete audio recordings and urine samples for analyses. Providers asked about illicit drug use in 81% of the visits. One hundred twenty-three patients (29%) disclosed any current or past illicit drug use; 48 patients (11%) disclosed current use of marijuana while pregnant. One hundred and forty-five samples (34%) tested positive for one or more substances; marijuana was most commonly detected (N = 114, 27%). Of patients who tested positive for any substance, 66 (46%) did not disclose any use; only 36% of patients who tested positive for marijuana disclosed current use. CONCLUSION: Although marijuana is illegal in Pennsylvania, a high proportion of pregnant patients used marijuana, with many not disclosing use to their obstetric care providers.
PURPOSE: To assess use, screening, and disclosure of perinatal marijuana and other illicit drugs during first obstetric visits. DESIGN: Observational study that qualitatively assesses provider screening and patient disclosure of substance use. SETTING: Study sites were five urban outpatient prenatal clinics and practices located in Pittsburgh, Pennsylvania. PARTICIPANTS: Pregnant patients and obstetric providers were recruited as participants. METHODS: We audio recorded patient-provider conversations during first obstetric visits and obtained patient urine samples for drug analyses. Audio recordings were reviewed for provider screening and patient disclosure of illicit drug use. Urine analyses were compared with audio recordings to determine disclosure. RESULTS: Four hundred and twenty-two pregnant patients provided complete audio recordings and urine samples for analyses. Providers asked about illicit drug use in 81% of the visits. One hundred twenty-three patients (29%) disclosed any current or past illicit drug use; 48 patients (11%) disclosed current use of marijuana while pregnant. One hundred and forty-five samples (34%) tested positive for one or more substances; marijuana was most commonly detected (N = 114, 27%). Of patients who tested positive for any substance, 66 (46%) did not disclose any use; only 36% of patients who tested positive for marijuana disclosed current use. CONCLUSION: Although marijuana is illegal in Pennsylvania, a high proportion of pregnant patients used marijuana, with many not disclosing use to their obstetric care providers.
Entities:
Keywords:
Communication; Health focus: illicit drug use; Marijuana; Outcome measure: behavioral; Physician Counseling; Pregnant Women; Prenatal Care; Prevention Research. Manuscript format: research; Research purpose: descriptive; Setting: outpatient obstetrics clinics and offices; Strategy: patient-provider screening communication; Study design: qualitative; Target population age: adult reproductive-age women (18 to 44 years); Target population circumstances: pregnant women and obstetric care providers
Authors: Gale A Richardson; Christopher Ryan; Jennifer Willford; Nancy L Day; Lidush Goldschmidt Journal: Neurotoxicol Teratol Date: 2002 May-Jun Impact factor: 3.763
Authors: Judy C Chang; Jill A Tarr; Cynthia L Holland; Natacha M De Genna; Gale A Richardson; Keri L Rodriguez; Jeanelle Sheeder; Kevin L Kraemer; Nancy L Day; Doris Rubio; Marian Jarlenski; Robert M Arnold Journal: Drug Alcohol Depend Date: 2019-01-11 Impact factor: 4.492
Authors: Marian Jarlenski; Caroline Hogan; Debra L Bogen; Judy C Chang; Lisa M Bodnar; Elizabeth Van Nostrand Journal: Womens Health Issues Date: 2017-01-24
Authors: Cynthia L Holland; Michelle Abena Nkumsah; Penelope Morrison; Jill A Tarr; Doris Rubio; Keri L Rodriguez; Kevin L Kraemer; Nancy Day; Robert M Arnold; Judy C Chang Journal: Patient Educ Couns Date: 2016-06-04
Authors: Suena H Massey; Daniel K Mroczek; David Reiss; Emily S Miller; Jessica A Jakubowski; Eileen K Graham; Shannon M Shisler; Meaghan McCallum; Marilyn A Huestis; Jody M Ganiban; Daniel S Shaw; Leslie D Leve; Rina D Eiden; Laura R Stroud; Jenae M Neiderhiser Journal: Neurotoxicol Teratol Date: 2018-06-07 Impact factor: 3.763
Authors: Kathleen E Trocin; Nicole I Weinstein; Emmanuel A Oga; Katrina S Mark; Victoria H Coleman-Cowger Journal: J Addict Med Date: 2020 Mar/Apr Impact factor: 4.647